Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis D Adams, A Gonzalez-Duarte, WD O’Riordan, CC Yang, M Ueda, ... New england journal of medicine 379 (1), 11-21, 2018 | 2762 | 2018 |
Inotersen treatment for patients with hereditary transthyretin amyloidosis MD Benson, M Waddington-Cruz, JL Berk, M Polydefkis, PJ Dyck, ... New England Journal of Medicine 379 (1), 22-31, 2018 | 1393 | 2018 |
In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration K Suzuki, Y Tsunekawa, R Hernandez-Benitez, J Wu, J Zhu, EJ Kim, ... Nature 540 (7631), 144-149, 2016 | 1276 | 2016 |
Sirolimus (RAPAMYCIN)-BASED therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine: 1, 2 CG Groth, L Bäckman, JM Morales, R Calne, H Kreis, P Lang, JL Touraine, ... Transplantation 67 (7), 1036-1042, 1999 | 1097 | 1999 |
Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial T Coelho, LF Maia, A Martins da Silva, M Waddington Cruz, ... Neurology 79 (8), 785-792, 2012 | 912 | 2012 |
High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients F Maduell, F Moreso, M Pons, R Ramos, J Mora-Macià, J Carreras, ... Journal of the American Society of Nephrology 24 (3), 487-497, 2013 | 900 | 2013 |
In vivo amelioration of age-associated hallmarks by partial reprogramming A Ocampo, P Reddy, P Martinez-Redondo, A Platero-Luengo, F Hatanaka, ... Cell 167 (7), 1719-1733. e12, 2016 | 849 | 2016 |
Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus F Vincenti, S Friman, E Scheuermann, L Rostaing, T Jenssen, ... American Journal of Transplantation 7 (6), 1506-1514, 2007 | 758 | 2007 |
Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial FP Schena, MD Pascoe, J Alberu, M del Carmen Rial, R Oberbauer, ... Transplantation 87 (2), 233-242, 2009 | 699 | 2009 |
Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft Recipients12 H Kreis, JM Cisterne, W Land, L Wramner, JP Squifflet, D Abramowicz, ... Transplantation 69 (7), 1252-1260, 2000 | 698 | 2000 |
Sirolimus and secondary skin-cancer prevention in kidney transplantation S Euvrard, E Morelon, L Rostaing, E Goffin, A Brocard, I Tromme, ... New England Journal of Medicine 367 (4), 329-339, 2012 | 663 | 2012 |
Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study) A Durrbach, JM Pestana, T Pearson, F Vincenti, VD Garcia, J Campistol, ... American Journal of Transplantation 10 (3), 547-557, 2010 | 620 | 2010 |
Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation JM Campistol, J Eris, R Oberbauer, P Friend, B Hutchison, JM Morales, ... Journal of the American Society of Nephrology 17 (2), 581-589, 2006 | 615 | 2006 |
Interspecies chimerism with mammalian pluripotent stem cells J Wu, A Platero-Luengo, M Sakurai, A Sugawara, MA Gil, T Yamauchi, ... Cell 168 (3), 473-486. e15, 2017 | 580 | 2017 |
Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review A Gutierrez-Dalmau, JM Campistol Drugs 67, 1167-1198, 2007 | 489 | 2007 |
In vivo target gene activation via CRISPR/Cas9-mediated trans-epigenetic modulation HK Liao, F Hatanaka, T Araoka, P Reddy, MZ Wu, Y Sui, T Yamauchi, ... Cell 171 (7), 1495-1507. e15, 2017 | 470 | 2017 |
Directed differentiation of human pluripotent cells to ureteric bud kidney progenitor-like cells Y Xia, E Nivet, I Sancho-Martinez, T Gallegos, K Suzuki, D Okamura, ... Nature cell biology 15 (12), 1507-1515, 2013 | 392 | 2013 |
Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study OB Suhr, T Coelho, J Buades, J Pouget, I Conceicao, J Berk, H Schmidt, ... Orphanet journal of rare diseases 10, 1-9, 2015 | 356 | 2015 |
Conversion to sirolimus: a successful treatment for posttransplantation Kaposi’s sarcoma12 JM Campistol, A Gutierrez-Dalmau, JV Torregrosa Transplantation 77 (5), 760-762, 2004 | 355 | 2004 |
Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial F Fakhouri, M Hourmant, JM Campistol, SR Cataland, M Espinosa, ... American journal of kidney diseases 68 (1), 84-93, 2016 | 326 | 2016 |